Acute Kidney Injury Among Pediatric Cancer Patients At South Egypt Cancer Institute

Assiut University2 enrolled

Overview

Cancer is the second most frequent cause of premature death in children. The incidence of pediatric cancer varies by region and country, but it is generally considered rare with an estimated 300,000 new cases diagnosed worldwide. Acute kidney injury in pediatric cancer patients refers to the sudden and often temporary loss of renal function, which can lead to a variety of complications if not treated correctly.

* Primary: To determine the cumulative incidence of AKI using KDIGO criteria in pediatric patients with malignancy in South Egypt Cancer Institute (SECI) * Secondary: 1. Incidence of Hospital-acquired and community-acquired AKI 2. Asses the risk factors of the incidence of AKI 3. To determine in-hospital outcome (time to in-hospital death, length of hospital stay, and time to kidney recovery) of AKI. This is a prospective study that will be carried out in the Paediatric Oncology and Haematological Malignancies Department including patients diagnosed with malignant tumours and hospitalized from 1st April 2023 for one year duration.

Study Type

OBSERVATIONAL

Enrollment

Conditions

To Determine the Cumulative Incidence of AKI Using KDIGO Criteria in Pediatric Patients With Malignancy in South Egypt Cancer Institute (SECI)

Interventions

kidney function testDIAGNOSTIC_TEST

blood sample for kidney function test

Eligibility

Sex: ALLMin age: 30 DaysMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * • Children of both sexes (aged from 1 month to 18 years at diagnosis) * Patients with either hematological malignancies or solid tumors admitted to the Paediatric Oncology and Haematological Malignancies Department Exclusion Criteria: * Children who had an unconfirmed cancer diagnosis. * Children more than 18 years at diagnosis. * Children with preexisting chronic kidney disease (CKD) that defined as the presence of structural or functional kidney damage that persist over minimum of three month * The patient underwent hematopoietic stem cell transplantation. Patients with 1 s.Cr level. * Patient underwent renal transplant.

Outcomes

Primary Outcomes

To determine the cumulative incidence of AKI using KDIGO criteria in pediatric patients with malignancy in South Egypt Cancer Institute (SECI)

Time frame: from November 2023 till November 2024

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.